United Healthcare not required to give time limits notice

A judge has granted United Healthcare’s motion to partially dismiss a participant's claim to recover benefits under the Employee Retirement Income Security Act (ERISA) because regulations don't require United to provide any time limits for review procedures in the final letter denying benefits to participants, reported BNA.

The U.S. District Court for Utah Judge Dale A. Kimball granted United's motion to deny benefits to Michael C.D.'s son for residential healthcare treatment at two medical facilities. Judge Kimball said that although providing time limits in denial letters for bringing a lawsuit under ERISA may be a good idea and helpful to claimants, it isn't required under the governing regulations.

They had informed Michael C.D. of his right to file a lawsuit under ERISA, but didn't specify the time limit for doing so. United ERISA regulations only require initial denial letters to include time limits applicable to an administrator's internal review procedures and under these regulations there is no requirement to include time limits for review procedures in final denial letters.

Michael C.D. argued in court that United was required to notify him in the denial letters of the limitations period and the date the period began to run while United stated that he had filed his claims after the expiration of the one-year contractual limitations period provided in the plan.

The courts ruled in favor of United, stating that the clause on contractual limitations was “sufficiently clear for the average plan participant to determine both the limitation period and the date that the period begins to run.”

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.